The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 17, 2022
Filed:
Oct. 28, 2019
Helmholtz-zentrum Für Infektionsforschung Gmbh, Braunschweig, DE;
Medizinische Hochschule Hannover, Hannover, DE;
Twincore, Zentrum Für Experimentelle Und Klinische Infektionsforschung Gmbh, Hannover, DE;
Mark Brönstrup, Braunschweig, DE;
Hans-Peter Prochnow, Braunschweig, DE;
N.V. Suryanarayana Birudukota, Braunschweig, DE;
Thomas Schulz, Hannover, DE;
Martin Messerle, Hannover, DE;
Thomas Pietschmann, Hannover, DE;
Sibylle Haid, Hannover, DE;
Sebastian Blockus, Hamburg, DE;
Christine Laqmani-Goffinet, Berlin-Steglitz, DE;
Sergej Franz, Hannover, DE;
Dominic Howard Banda, Ghent, BE;
Helmholtz-Zentrum Für Infektionsforschung GMBH, Braunschweig, DE;
Medizinische Hochschule Hannover, Hannover, DE;
Twincore Zentrum Für Experimentelle und Klinische Infektionsforschung GMBH, Hannover, DE;
Abstract
The present invention relates to novel labyrinthopeptin derivatives. These labyrinthopeptin derivatives are useful for the treatment of infectious diseases, such as an infectious disease caused by an infection with human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), cytomegalovirus (CMV/HCMV), dengue virus (DENV), chikungunya virus (CHIKV), tick-borne encephalitis virus (TBEV; FSME virus), vesicular stomatitis Indiana virus (VSV), zika virus (ZIKV) and/or hepatitis C virus (HCV). Said labyrinthopeptin derivatives are also useful for analyzing the mode of action of labyrinthopeptins. Also encompassed by the present invention are labyrinthopeptins for use in treating an infectious disease, in particular an infectious disease caused by an infection with any one of the viruses selected from RSV, KSHV, CMV, CHIKV, TBEV, VSV, ZIKV and HCV. The invention further relates to a combination of labyrinthopeptin A1 and A2 for use as a medicament, e.g. for treating an infectious disease caused by an infection with RSV, KSHV, CMV, DENV, CHIKV, TBEV, VSV, ZIKV and/or HCV.